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Our objective was to develop a working deﬁnition of nonresponse to analgesic treatment of arthritis,focusing on the measurement
of pain on the 0–100mm pain visual analog scale (VAS). We reviewed the literature to assess the smallest detectable diﬀerence
(SDD), the minimal detectable change (MDC), and the minimal clinically important diﬀerence (MCID). The SDD for
improvement reported in three studies of rheumatoid arthritis was 18.6, 19.0, and 20.0. The median MDC was 25.4 for 7 studies
of osteoarthritis and 5 studies of rheumatoid arthritis (calculated for a reliability coeﬃcient of 0.85). The MCID increased with
increasing baseline pain score. For baseline VAS tertiles deﬁned by scores of 30–49, 50–65, and >65, the MCID for improvement
was, respectively, 7–11 units, 19–27 units, and 29–37 units. Nonresponse can thus be deﬁned in terms of the MDC for low baseline
pain scores and in terms of the MCID for high baseline scores.
1.Introduction
Nonsteroidal anti-inﬂammatory drugs (NSAIDs) are the
ﬁrst-line treatment for osteoarthritis [1] and a corner-
stone of pharmacologic management of other arthritic and
rheumatologic illnesses [2]. The dichotomous classiﬁcation
of patients into responders and nonresponders to NSAIDs
began in the 1970s [3]. Walker et al. provided evidence of the
validity of the responder/nonresponder thesis in rheumatoid
arthritis and osteoarthritis [4].
Both the American College of Rheumatology (ACR) and
the European League Against Rheumatism (EULAR) have
developed response criteria for rheumatoid arthritis. The
ACR criteria are based on a core set of measures with 7 com-
ponents[5].EULARresponsecriteriaarebasedonthemulti-
item Disease Activity Score 28 (DAS28) [6]. A composite
index of patient-reported pain, physical function, and global
assessmentappearstobeasgoodastheentireACRcoresetor
the DAS28 for determining response to treatment in clinical
trials of rheumatoid arthritis [7].
The most recent deﬁnition of response to NSAID
treatment in osteoarthritis was determined by a joint
task force comprising members of the Outcome Mea-
sures in Rheumatology (OMERACT) committee and the
Osteoarthritis Research Society International (OARSI) [8].
In the OMERACT-OARSI guidelines, response is a binary,
composite endpoint based on three patient-reported core
outcome measures: pain, physical function, and the patient
global assessment. Of these three, pain is considered the
primary outcome measure of interest [9].
In clinical trials, deﬁnitions of the eﬀectiveness of
analgesic therapies for arthritic pain are focused on response
to treatment. In clinical practice, however, decisions to
change the analgesic dose or drug for an individual patient2 International Journal of Inﬂammation
are based on nonresponse to the existing treatment. We
sought to develop a working deﬁnition of nonresponse to
analgesic treatment, focusing on the measurement of pain
with the 0–100mm visual analog scale (VAS). We posited
that nonresponse could be measured in terms of (i) the
smallest amount of change on the pain VAS that can be
reliably measured or (ii) the smallest change that the patients
report as important. The ﬁrst of these concepts, the smallest
amount of change that can be reliably measured, is reported
in the literature as either the smallest detectable diﬀerence
(SDD)ortheminimaldetectablechange(MDC).Thesecond
concept is reported as the minimal clinically important
diﬀerence (MCID).
2.LiteratureSearch
Searches were carried out for randomized clinical trials
(RCTs) of patient-reported measurement of chronic pain in
arthritis. Articles known to the authors were supplemented
by searches of PubMed performed in June 2010 with
the following algorithms: reliability AND pain AND VAS;
∗arthritis AND “Drug Resistance” [MeSH Terms] AND
“anti-inﬂammatory agents, Nonsteroidal” [MeSH Terms]
AND“humans”[MeSHTerms];NSAID-refractory;NSAID∗
AND (non-respon∗ OR nonrespon∗); refractory [title word]
AND osteoarthritis [title word]; refractoriness [title word]
AND concept. These searches resulted in 318 unique items.
Articles were screened for those reporting parameters of
the English 0–100mm pain VAS: the SDD, the MCID,
or the reliability, from which the MDC can be calcu-
lated.
3. The Smallest Detectable Difference
The SDD on a measurement scale is that amount of
diﬀerence for which anything smaller cannot be reliably
distinguished from random error in the measurement [12].
Therearetwomethods of estimating this quantity in original
scale units [12]. The ﬁrst is the limits of agreement method
[13], and the term SDD is usually used when the parameter
is calculated by this method. The SDD is applicable to
longitudinal data [14], and thus the limits of agreement
method is often used to assess agreement between test and
retest scores [12, 13]. The mean diﬀerence between test and
retest scores and its SD are calculated, and the SDD is the
95% conﬁdence interval (CI) of the diﬀerence, that is, 1.96
times the SD of the diﬀerence between scores [11].
The SDD reported in three RCTs of rheumatoid arthritis,
g i v e na sn e g a t i v ec h a n g eo ri m p r o v e m e n t ,w a s−18.6, −19.0,
and −20.0 (Table 1). SDDs of this magnitude constitute
half or more of the mean baseline pain score in VAS units,
suggesting that a very large change in pain status is required
before that change is detectable.
4.MinimalDetectable Change
The second method for calculating the SDD is from the
standard error of the measurement (SEM) [15, 16], and,
when calculated in this way, it is usually termed the MDC
(it is also referred to as the “smallest real diﬀerence” [17]
and the “tolerance interval” [18]). The SEM is a function
of the standard deviation (SD) of the study sample and
the reliability of the measurement instrument [19]. The
reliability coeﬃcient (RC) may be the test-retest reliability
or an intraclass correlation coeﬃcient. The MDC is thus
applicable to cross-sectional data [14]. The MDC is given by
MDC =± 1.96×
√
2×SEM where1.96derivesfromthe95%
CI. The SEM is derived from the SD and the RC as follows:
SEM = SD ×

(1 −RC).
The MDC was rarely reported in published RCTs of
rheumatoid arthritis or osteoarthritis. Hence, we calculated
it for RCTs reporting mean (SD) values from the pain VAS.
We searched for RC values in the literature. Six RCTs of
rheumatoid arthritis patients (the three in Table 1 and three
additional publications) reported RCs of 0.74 [20], 0.75
[12], 0.88 [21], 0.88 [10], 0.94 [11], and 0.94 [22]. The
medianRCwas0.88.WecalculatedtheMDCforrheumatoid
arthritis [10, 11, 20, 21, 23, 24] and osteoarthritis [25–30]
RCTs reporting mean pain VAS score at baseline using three
arbitrary RC values (0.75, 0.85, and 0.95) spanning the range
found in the literature.
As expected based on the above formulas, the MDC
was smaller (i.e., a more precise measurement could be
obtained) for higher values of RC (Figure 1). For example, in
osteoarthritis, the median MDCs were 10.7, 18.6, and 24.0
for RCs of 0.95, 0.85, and 0.75, respectively. In addition,
the data appear to indicate a trend toward smaller MDCs at
higher baseline pain scores (Figure 1). By linear regression
analysis, the slope of the line through all the data points
(osteoarthritis and rheumatoid arthritis) with RC = 0.85
(−0.28) was statistically signiﬁcant at P = 0.005 (as were the
slopesattheothertwoRCvalues).Thisﬁnding suggeststhat,
when the patient’s pain is greater, the instrument can reliably
detect smaller diﬀerences in pain.
For a given RC, the MDC was larger for rheumatoid
arthritis than for osteoarthritis (Figure 1). (The median
MDCs for rheumatoid arthritis were 15.8, 27.3, and 35.3
for RCs of 0.95, 0.85, and 0.75, resp.) Linear regression
analyses of rheumatoid arthritis and osteoarthritis trials
as separate groups did not produce statistically signiﬁcant
correlations between baseline pain and MDC. Rather than
MDC being inversely correlated with baseline pain score, the
datamaybeinterpretedasadiﬀerencebetweenosteoarthritis
and rheumatoid arthritis, combined with the fact that the
rheumatoid arthritis trials assessed here included patients
with lower baseline pain scores than the patients in the
osteoarthritis trials.
5. MinimalClinicallyImportant Difference
Distinct from the concepts of SDD and MDC is that of the
minimal clinically important diﬀerence (MCID). Jaeschke
et al. deﬁned the MCID as “the smallest diﬀerence in
score in the domain of interest which patients perceive
as beneﬁcial and which would mandate...a change in the
patient’s management” [31].International Journal of Inﬂammation 3
Table 1: Smallest detectable diﬀerence (SDD) of the 0–100mm pain VAS reported in studies of rheumatoid arthritis.
Study N Baseline pain VAS scorea SDD
Mean SD Absolute valueb A s%o fp a i nV A Ss c o r e
Uhlig et al. 2009 [10] 28 29.5 23.7 −18.6, +26.0 ±76%
Pincus et al. 2008 [11] 264 39.8c 29.1c −19.0, +19.4 ±48%
Lassere et al. 2001 [12]2 4 3 7 — −20, +16.3 ±49%
SD: standard deviation; SDD: smallest detectable diﬀerence; VAS: visual analog scale.
a0–100mm pain VAS from 0, no pain, to 100, very severe pain.
bAll 10-mm scale values were converted to a 100-point scale by multiplying by ten.
cValues provided by T. Pincus and C. Swearingen for the “line 1” scores (see original article).
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Figure 1: Minimal detectable change by baseline pain score,
for diﬀerent values of the reliability coeﬃcient. Closed symbols
show data for rheumatoid arthritis, while open symbols depict
osteoarthritis. Squares show MDC at RC = 0.75, diamonds at RC
= 0.85, and triangles at RC = 0.95.
The measurement of the MCID for a scale requires a
reference standard (or “external criterion”; also referred to as
an “anchor” [32])—frequently the patient global assessment
(PGA) of treatment eﬀect. The four RCTs reporting the
MCID on the pain VAS used the PGA as an anchor (Table 2).
Although the MCID values for improvement reported in
these RCTs fall within a relatively narrow range (−11.1
to −19.9), there was no consensus on the deﬁnition of
the MCID (Table 2). For the purposes of this paper, the
MCID is expressed as the amount of change on the pain
VAS corresponding to a speciﬁc degree of change on the
PGA.
Tubach et al. [30] assessed only the improvement aspect
of the MCID and deﬁned the minimal clinically important
improvement (MCII) as the minimum improvement (on
the pain VAS) reported by 75% of osteoarthritis patients
who ranked their response as “good” on the PGA. By
this deﬁnition, the MCII was −15.3 for hip osteoarthritis
and −19.9 for knee osteoarthritis (Table 2). The MCID for
osteoarthritis pain was also investigated in terms of the
“minimal perceptible clinical improvement” (MPCI) [26].
This parameter was deﬁned as the change in the pain VAS
score corresponding to a change from “none” to “poor”
in the PGA, and the reported value was −11.1. To achieve
a direct comparison between the MPCI and the MCII
described above, we examined the 75th percentile of patients
with a PGA of “good” in Ehrich et al. [26] and found that
they had a minimum change of approximately −33 on the
painVAS,amuchlargerchangethanthatreportedbyTubach
et al. [30].
The MCID on the pain VAS reported by Pope et al. for
rheumatoid arthritis was similar to that for osteoarthritis
(Table 2)[ 24]. Pope et al. anchored the pain score in a
patient-reported overall assessment of disease status [24].
T h e i rs t u d ya n da n o t h e ro nb a c kp a i n[ 18] assessed the
MCID for both improvement and worsening, and both RCTs
found that the MCID was larger for improvement than for
worsening: −11.8versus+6.8intheRAstudyand −18versus
+8 in the back pain study (Table 2).
The MCID on the pain VAS is not a ﬁxed value;
it depends to some extent on the baseline pain score
[33]. To investigate this idea, Tubach et al. divided their
study population into tertiles based on baseline pain scores
[30]. When knee osteoarthritis patients were categorized
according to their baseline pain scores, the MCIIs were 11,
27, and 37 units for the lowest, middle, and highest tertiles,
respectively. For hip osteoarthritis patients, these values were
7, 24, and 30. These ﬁndings are depicted in Figure 2.
The study of back pain also reported MCIDs according
to baseline pain score [18]. In this study, baseline pain scores
were divided into three categories: mean minus 2∗SD, mean,
a n dm e a np l u s2 ∗SD, corresponding to scores of 35, 64,
and 93, respectively. These scores ﬁt the tertiles described
by Tubach et al. As shown in Figure 2, the MCIDs for
improvement in each tertile were 9, 19, and 29, respectively.
The MCID of −11.9 reported by Pope et al. [24]a tam e a n
baseline score of 42.3 also ﬁts in well with the data in
Figure 2.
6. Discussion
TwooftheSDDsreportedintheliterature(−18.6and −19.0;
Table 1) ﬁt well onto the graph of MDC values in Figure 1
(not shown). The corresponding RCs of 0.88 [10] and 0.94
[11], respectively, may explain why the SDDs fall squarely
between the overall median values of MDC at RC = 0.95
(14.7) and RC = 0.85 (25.4) on the graph. The third SDD
(−20) [12], which had an RC of 0.75, did not ﬁt the graph
for that MDC data set.4 International Journal of Inﬂammation
Table 2: Minimal clinically important diﬀerence on the 0–100mm pain VAS.
Study Patients Anchor MCID
Type Points Responses Deﬁnition Points on
anchor scale
Units on
VASa
Pope et al.
2009 [24]
RA PGA 5
Much worsened, somewhat
worsened, same, somewhat
improved, much improved
Diﬀerence between “same” and
“somewhat improved or
somewhat worsened”
±1 point −11.9, +6.8
Tubach et al.
2005 [30]
OA PGA 5 None, poor, fair, good,
excellent
Diﬀerence between “none” and
“good” response +3 points
−19.9 (knee)
−15.3 (hip)
H¨ agg et al.
2003 [18]
Back pain PGA 4 Worse, unchanged, better,
much better
Diﬀerence between “unchanged’
and “better” or “worse”
±1 point −18, +8
Ehrich et al.
2000 [26]
OA PGA 5 None, poor, fair, good,
excellent
Diﬀerence between “none” and
“poor” response on the PGAb +1 point −11.1
MCID; minimal clinically important diﬀerence; PGA: patient global assessment of response.
aNegative values indicate improvement, and positive ones indicate deterioration.
bDeﬁned as minimal perceptible clinical improvement.
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Figure 2: Minimal clinically important diﬀerence by tertile of
baseline VAS score. The light, medium, and dark gray sections
of the VAS (30–49, 50–65, and >65) correspond to the rounded
tertiles of baseline pain VAS scores reported by Tubach et al. [30].
ArrowsdepicttheMCIDforimprovementreportedbyTubachetal.
(osteoarthritis of knee and hip) [30] and H¨ agg et al. (back pain)
[18].
The calculated values of MDC decreased with increasing
baseline pain score, suggesting that small diﬀerences in pain
can be measured more precisely at higher levels of pain.
The MDC is a function of the SD of the mean group-
level pain score. Is the SD for patient-reported pain actually
smaller at higher levels of pain? According to these data,
yes. Linear regression analyses of the SD versus the baseline
pain score yielded a statistically signiﬁcant slope (−0.26;
P = 0.005) for the combined data set, but statistically
nonsigniﬁcant slopes when osteoarthritis and rheumatoid
arthritis were analyzed separately. There was also no linear
relationship between the RC (the other variable on which
MDC depends) and the baseline pain. We interpret this to
mean that the relationship between the MDC and baseline
pain is an inherent characteristic of the pain VAS rather than
a byproduct of physiologically diﬀerent disease states or the
statistical reliability of the scale.
The trend of the MCID is opposite that of the MDC—
it is larger at higher baseline pain levels. Thus it appears
that,althoughsmalldiﬀerencesinpainarereliablydetectable
in patients with severe pain, these patients require a larger
amount of pain relief in order to report being satisﬁed
with the change they experience. In the context of Figure 2,
a patient with severe pain (score >65) needs a change to
the moderate pain category (50–65) to view it as clinically
important.
The relationship between MCID and baseline severity
may apply to other measures in addition to the pain VAS.
The RCTs included in our analysis often reported physical
function and PGA as well and in Tubach et al. [30], for
instance, the MCID for both the WOMAC physical function
score and the PGA increased with increasing baseline scores.
Future analyses should investigate the relationship between
baseline pain and these other measures of patient response.
The OMERACT-OARSI criteria for response to treat-
ment include both absolute and relative changes on the
pain VAS. As described by Pham et al. [8] ,ar e s p o n d e r
experiences either (i) ≥50% improvement on the pain VAS,
deﬁned as at least 20units, or (ii) ≥20% improvement,
deﬁned as at least 10units, in combination with above-
threshold improvements on at least one other measure of
patient response, that is, physical function or the PGA. The
ACR criteria have a similar deﬁnition of response, graded by
percentage improvements (20%, 50%, and 70%) in tender
and swollen joint counts and 3 of the 5 other outcome
measures (of which pain is one). However, the ACR20,
ACR50, andACR70 response levelsarenot linked to absolute
unitimprovementsonthepainVAS.Thequestioniswhether
the pain VAS is sensitive enough to detect the amount of
change required for a deﬁnition of ‘response’ under either
set of criteria.
At RC = 0.85, the median MDC on the pain VAS
is 25.4units (for osteoarthritis and rheumatoid arthritis
combined), which is greater than the minimum of 10–
20units required to be considered a responder in the
OMERACT-OARSI criteria. As a percentage of the baselineInternational Journal of Inﬂammation 5
pain, the median MDC is 46.1% (at RC = 0.85), which
is within the threshold of improvement required for a
response by deﬁnition (i) above, but outside the range
required in deﬁnition (ii). This amount of change also
meets the deﬁnition of an ACR20 response. Similarly, the
SDDs in patients with RA, as shown in Table 1 (48%,
49%, and 76%), indicate that the smallest detectable change
in pain is greater than the minimum amount considered
necessary for a deﬁnition of “response” by both sets of
criteria.
The median values of MCID for each tertile in Figure 2
are 9, 24, and 30units overall and 9, 25.5, and 33.5units
for osteoarthritis only. Whether the results are combined or
osteoarthritisisconsideredseparately,onlypatientsattaining
the MCID in the middle and highest tertiles can be classiﬁed
as responders by the OMERACT-OARSI criteria. Those in
the lowest tertile might perceive an improvement in their
pain as clinically important but still be classiﬁed as a
nonresponder.TakingthemidpointofeachtertileinFigure 2
as the baseline pain score and the overall median value of
MCID of each tertile as the true MCID, the relative values of
MCID are 22.5%, 47.0%, and 36.4% for baseline pain scores
of 30–49, 50–65, and >65. Thus the MCID for each tertile is
less than the amount required for a response by OMERACT-
OARSI deﬁnition (i) mentioned before.
7. Conclusions
We have shown that the smallest decrease in pain that
can be reliably measured, the MDC, is smaller than the
MCID for scores of >65 on the 0–100pain VAS, but not for
scores of <50. Improvements in the middle of the pain VAS
may or may not be measurable depending on the type of
pain, the baseline score, and the RC of the pain VAS. We
concludethat,forbaselinepainscoresabove65,nonresponse
can be deﬁned as any change on the pain VAS that is
smaller than the MCID. For patients with scores below 65,
a change less than the MDC can be considered nonresponse;
however, improvements that are greater than the MDC but
not considered clinically important by the patient may also
justify a change in therapy.
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